Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127352032 | 12735203 | 2 | F | 2014 | 20160830 | 20160912 | 20160921 | PER | US-JNJFOC-20160717447 | JANSSEN | 0.00 | A | M | Y | 86.30000 | KG | 20160921 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127352032 | 12735203 | 1 | PS | XARELTO | RIVAROXABAN | 1 | Oral | Y | N | 22406 | 10 | MG | TABLET | QD | |||||
| 127352032 | 12735203 | 2 | SS | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | TABLET | QD | |||||||
| 127352032 | 12735203 | 3 | SS | PLETAL | CILOSTAZOL | 1 | Oral | 0 | 50 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127352032 | 12735203 | 1 | Peripheral vascular disorder |
| 127352032 | 12735203 | 2 | Peripheral vascular disorder |
| 127352032 | 12735203 | 3 | Peripheral vascular disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127352032 | 12735203 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127352032 | 12735203 | Gastrointestinal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127352032 | 12735203 | 1 | 20140219 | 20140910 | 0 |